AU2002317519B2 - Multilayered polymer structure for medical products - Google Patents

Description

Regulation 3.2 Revised 2/98

AUSTRALIA

Patents Act, 1990

ORIGINAL

COMPLETE SPECIFICATION TO BE COMPLETED BY THE APPLICANT NAME OF APPLICANT: ACTUAL INVENTORS: ADDRESS FOR SERVICE: INVENTION TITLE: DETAILS OF ASSOCIATED APPLICATION NO: Baxter International Inc SIDNEY T SMITH LARRY A ROSENBAUM STEVEN GIOVANETTO BRADLEY BUCHANAN Y SAMUEL DING, SUCHUAN C FAN GREGG NEBGEN Peter Maxwell Associates Level 6 Pitt Street SYDNEY NSW 2000 MULTILAYERED POLYMER STRUCTURE FOR MEDICAL

PRODUCTS

Divisional of Australian Patent Application No. 95,735/98 (752,242) filed on 18 September 1998 The following statement is a full description of this invention including the best method of performing it known to us:m:\docs\981268\023791 .doc The present invention relates generally to multilayered polymeric structures for fabricating medical grade products and more specifically five-layered structures for fabricating medical solution containers and medical tubings.

In the medical field, where beneficial agents are collected, processed and stored in containers, transported, and ultimately delivered through tubes by infusion to patients to achieve thermpi~utic effects, materials which are used to fabricate the containers must have a unique combination of properties. For example in order to visually inspect solutions for particulate contaminants, the container must be optically transparent. To infuse a solution from a container by collapsing the container walls, without introducing air into the container, the material which fonns the walls must be sufficiently flexible to collapse upon draining. The material must be functional over a wide range of temperatures. The material must be capable of withstanding radiation sterilization without degrading its physical properties. The material must function at law temperatures by maintaining its flexibility and toughness as same medical solutions, and blood products are stored and transported in containers at temperatures iuch as -25 to A fuirther requirement is to minimize the environmental impact upon the disposal of the article fabricated from the material after its intended use. For those articles that are disposed of in landfills, it is desirable to use as little material as possible and avoid the incorporation of low molecular weight leachable components to construct the article.

Further benefits are realized by using a material which may be recycled by thermoplastically reprocessing the post-consumer article into other useful articles.

For those containers that are disposed of through incineration, it is necessary to use a material that minimizes or eliminates entirely the formation of inorganic acids which are environmentally harmful, irritating, and corrosive, or other products which are harmful, irritating, or otherwise objectionable upon incineration.

For ease of manufacture into useful articles, it is desirable that the material be sealable using radio frequency sealing techniques generally at about 27.12 ML-Iz. Therefore, the material should possess sufficient dielectric loss properties to convert the RE energy to thermal energy.

It is also desirable that the material be free from or have a low content of low molecular weight additives such as plasticizers, slip agents, stabilizers and the like which could be released into the medications or biological fluids or tissues, contaminating such substances being stored or processed in such devices.

In many medical product applications, it is desirable to provide a multilayered structure that provides a barrier to the passage of oxygen, carbon dioxide, and water. For medical solutions that are packaged having a desired concentration of a drug or solute, the baffler to water helps maintain this concentration by preventing water from escaping from the container. In solutions that have a buffer to prevent pH changes, such as a commonly used sodium bicarbonate buffer, the barrier to carbon dioxide helps maintain the buffer by preventing carbon dioxide from escaping from the container. For medical solutions containing labile species, the oxygen baffler helps prevent the ingress of oxygen which can oxidize proteins or amino acids rendering the solution ineffective for its intended purpose.

Ethylene vinyl alcohol (EVOH) is known for use as an oxygen baffler in multilayer films. One commnercially available EVOH layered structure is sold by Baffler Film 4 Corporation under the product designation BF-405 for thermoforming into food packaging.

It is believed that the BF-405 film has an outer layer of nylon, a core layer of EVOH and an inner layer of a metallocene-catalyzed ultra-low density polyethylene. These layers are formed into a layered structure or film by a blown film process. This film has an oxygen transmission rate, for a film 2.6 mils in thickness, of 0. 05 cc/ 100 sq.in./24 hrs.

The BF-405 film is unacceptable for medical applications as slip agents must be used during the processing of the film. Such slip agents include low molecular weight components that are soluble in water and are capable of leaching out into the medical solution which it contacts. Thus, if such film were constructed into a medical container and filled with a medical solution, it would likely lead to an unacceptably high extractable content in the contained medical solution.

There are numerous US patents that disclose EVOH barrier films. For example, United States Patent No. 4,254,169 provides barrier films having layers of EVOH and polyolefins. The '169 Patent discloses an adhesive for bonding the EVOH to polyolefins which includes a high density polyethylene grafted with a fused-ring carboxylic acid anhydride blended with an unmodified polyolefin. (Col. 2, line 65-col. 3, line 21). In many of the examples, the '169 Patent discloses adding a slip agent to make the outer surface of the films more slippery. (See Tables I and II and col. 5, lines 35-37) United States Patent No. 4,397,916 discloses multilayered EVOH structures in which the EVOH is attached to other layers such as polyolefins by a layer of a graft-modified ethylene resin grafted with a carboxylic acid or a functional derivative thereof. The '916 Patent also provides for attaching nitrogen containing polymers such as nylons to polyolefins with the graft modified ethylene resins. The '916 Patent does not discuss limiting low molecular weight additives to reduce the amount of extractables. In fact the '916 encourages the use of slip agents, lubricants, pigments, dyes and fillers (Col. 6, lines 38-42) which could have a deleterious impact on the amount of extractables and on the optical transparency of the polymer blend.

United States Patent No. 5,164,258 discloses a multilayered structure containing EVOH as a barrier layer sandwiched between two layers of polyolefins. The polyolefin layers are intended to facilitate the escape of moisture which becomes absorbed in the barrier layer during a steam sterilization process. The polyolefin layers are attached to the EVOH layer with, for example, a maleic anhydride graft-modified polyethylene adhesive.

The '258 Patent discloses increasing the WVTR of one of the polyolefin layers by adding organic and inorganic fillers to the layer. (Col. 4, lines 22-59).

These fillers are likely to render the multilayered structure optically opaque.

According to one aspect of the invention there is provided a method of storing a medical solution containing a labile species comprising storing said solution in a flexible container, the container being comprised of an ethylene vinyl alcohol copolymer having an oxygen permeability of less than 0.2 cc/100 in 2 /24 hrs.

According to another aspect of the invention there is provided a container for storing a medical solution containing a labile species comprising: a labile species; and a flexible container of an ethylene vinyl alcohol copolymer having an oxygen permeability of less than 0.2 cc/100 in 2 /24 hrs.

in order that the invention may be more readily understood and put into practical effect, reference will now be made to the accompanying drawings in which: Fig. 1 shows a cross-sectional view of a five layered film structure of the present invention; Fig. 2 shows another embodiment of the present invention; and Fig. 3 shows yet another embodiment of the present invention.

While this invention is susceptible of embodiments in many different forms, and will herein be described in detail, preferred embodiments of the invention are disclosed with the understanding that the present disclosure is to be considered as exemplifications of the principles of the invention and are not intended to limit the broad aspects of the invention to the embodiments illustrated.

According to the present invention, multiple layered film structures are provided which meet the requirements set forth above.

Figure 1 shows a five layered film structure 10 having an outer layer 12, a core layer 14, an inner or solution contact layer 16 and two tie layers 18. One of each of the tie layers 18 is located between the core layer 14 and the outer layer 12 and the inner layer 16 and the core layer 14.

The core layer 14 is an ethylene vinyl alcohol copolymer having an ethylene-content of from about 25-45 mole percent (ethylene incorporated, as specified in EVALCA product literature). Kuraray Company, Ltd. produces EVOH copolymers under the tradename EVAL® which have about 25-45 mole percent of ethylene, and a melting point of about 150-195 C. Most preferably the EVOH has a ethylene content of 32 mole percent.

The outer layer preferably is a polyamide, polyester, polyolefin or other material that aids in the escape of water away from the core layer. Acceptable polyamides include those that result from a ring-opening reaction of lactams having from 4-12 carbons. This group of polyamides therefore includes nylon 6, nylon 10 and nylon 12. Most preferably, the outer layer is a nylon 12.

Acceptable polyamides also include aliphatic polyamides resulting from the condensation reaction of di-amines having a carbon number within a range of 2-13, aliphatic polyamides resulting from a condensation reaction of di-acids having a carbon number within a range of 2-13, polyamides resulting from the condensation reaction of dimer fatty acids, and amide containing copolymers. Thus, suitable aliphatic polyamides include, for example, nylon 66, nylon 6,10 and dimer fatty acid polyamides.

Suitable polyesters for the outer layer include polycondensation products of di-or polycarboxylic acids and di or poly hydroxy alcohols or alkylene oxides. Preferably, the polyesters are a condensation product of ethylene glycol and a saturated carboxylic acid such as ortho or isophthalic acids and adipic acid. More preferably the polyesters include polyethyleneterphthalates produced by condensation of ethylene glycol and terephthalic acid; polybutyleneterephthalates produced by a condensations of 1,4-butanediol and terephthalic acid; and polyethyleneterephthalate copolymers and polybutyleneterephthalate copolymers which have a third component of an acid component such as phthalic acid, isophthalic acid, sebacic acid, adipic acid, azelaic acid, glutaric acid, succinic acid, oxalic acid, etc.; and a diol component such as 1,4-cyclohexanedimethanol, diethyleneglycol, propyleneglycol, etc. and blended mixtures thereof.

Suitable polyolefins for the outer layer are the same as those specified for the inner layer set forth below. Preferably a polypropylene is used.

It is well known that the oxygen barrier properties of EVOH are adversely impacted upon exposure to water. Thus, it is important to keep the core layer dry. To this end, the outer layer should assist in the removal of water that makes its way to the core layer through the inner layer or otherwise to maintain the oxygen barrier properties of the core layer.

The inner layer is preferably selected from homopolymers and copolymers of polyolefins. Suitable polyolefins are selected from the group consisting of homopolymers and copolymers of alpha-olefins containing from 2 to about 20 carbon atoms, and more preferably from 2 to about 10 carbons. Therefore, suitable polyolefins include polymers and copolymers ofpropylene, ethylene, butene-1, pentene-1, hexene-1, heptene-1, octene-l, nonene-1 and decene-1. Suitable polyolefins further include lower alkyl and lower alkene acrylates and acetates and ionomers thereof. The term "lower alkyl" means alkyl groups having 1-5 carbon atoms such as ethyl, methyl, butyl and pentyl. The term "ionomer" is used herein to refer to metal salts of the acrylic acid copolymers having pendent carboxylate groups associated with monovalent or divalent cations such as zinc or sodium.

Most preferably, the inner layer is selected from ethylene a-olefin copolymers especially ethylene-butene-1 copolymers which are commonly referred to as ultra-low density polyethylenes (ULDPE). Preferably the ethylene a-olefin copolymers are produced using metallocene catalyst systems. Such catalysts are said to be "single site" catalysts because they have a single, sterically and electronically equivalent catalyst position as 2 opposed to the Ziegler-Natta type catalysts which are known to have a mixture of catalysts sites. Such metallocene catalyzed ethylene a-olefins are sold by Dow under the tradename AFFINITY, and by Exxon under the tradename EXACT. The ethylene a-olefins preferably have a density from 0.880-0.910 g/cc.

Suitable tie layers include modified polyolefins blended with unmodified polyolefins.

3 0 The modified polyolefins are typically polyethylene or polyethylene copolymers. The polyethylenes can be ULDPE, low density (LDPE), linear low density (LLDPE), medium density polyethylene (MDPE), and high density polyethylenes (HDPE). The modified polyethylenes may have a density from 0.850-0.95 g/cc.

The polyethylene may be modified by grafting with carboxylic acids, and carboxylic anhydrides. Suitable grafting monomers include, for example, maleic acid, fumaric acid, itaconic acid, citraconic acid, allylsuccinic acid, cyclohex-4-ene-1,2-dicarboxylic acid, 4methylcyclohex-4-ene- 1,2-dicarboxylic acid, bicyclo[2.2. 1]hept-5-ene-2,3-dicarboxylic acid, x-methylbicyclo[2.2. I ]hept-5-ene-2,3-dicarboxylic acid, maleic anhydride, itaconic anhydride, citraconic anhyride, allylsuccinic anhydride, citraconic anhydride, allylsuccinic anhydride, cyclohex-4-ene- 1,2-dicarboxylic anhydride, 4 -methylcyclohex-4-ene- 1,2dicarboxylic anhydride, bicyclo[2.2.1] hept-5-ene2,3-dicarboxylic anhydride, and xmethylbicyclo[2.2.1] hept-5-ene-2,2-dicarboxylic anhydride.

Examples of other grafting monomers include C 1 alkyl esters or glycidyl ester derivatives of unsaturated carboxylic acids such as methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, butyl acrylate, butyl methacrylate, glycidyl acrylate, glycidal methacrylate, monoethyl maleate, diethyl maleate, monomethyl maleate, diethyl maleate, monomethyl fumarate, dimethyl fumarate, monomethyl itaconate, and diethylitaconate; amide derivatives of unsaturated carboxylic acids such as acrylamide, methacrylamide, maleicmonoamide, maleic diamide, maleic N-monoethylamide, maleic N,N-dietylamide, maleic N-monobutylamide, maleic N,N dibutylamide, fumaric monoamide, fumaric diamide, fumnaric N-monoethylamide, fumaric N,N-diethylamide, fumaric N-monobutylamide and fumaric N,N-dibutylamide; imide derivatives of unsaturated carboxylic acids such as maleimide, N-butymaleimide and N-phenylmaleimide; and metal salts of unsaturated carboxylic acids such as sodium acrylate, sodium methacrylate, potassium acrylate and potassium methacrylate. More preferably, the polyolefin is modified by a fused ring carboxylic anhydride and most preferably a maleic anhydride.

The unmodified polyolefins can be selected from the group consisting of ULDPE, LLDPE, MDPE, HDPE and polyethylene copolymers with vinyl acetate and acrylic acid.

Suitable modified polyolefin blends are sold, for example, by DuPont under the tradename BYNEL®, by Chemplex Company under the tradename PLEXARg, and by Quantum Chemical Co. under the tradename PREXAR.

As can be seen in Figure 1, the preferred multilayered structure is asymmetrical about the core layer 14. That is to say, the solution contact layer 16 is thicker than the outer layer 12. It is well known that EVOH is hygroscopic. As the EVOH absorbs water its oxygen barrier properties are significantly reduced. The preferred structure 10 provides a relatively thin outer layer of a polyamide that assists in the escape of water away from the core layer 14. The solution contact layer 16 is a relatively thick layer of a polyolefin which has good water vapor barrier properties and serves to protect the core layer 14 from the ingress of water.

The relative thicknesses of the layers of the structure 10 is as follows: the core layer should have a thickness from 0.2-2.5 mil, more preferably from 0.7-1.3 mil or any range or combination of ranges therein. The outer layer 12 preferably has a thickness from 0.2-2.0 mil and more preferably 0.4-0.8 mil, or any range or combination of ranges therein. The inner layer 16 has a thickness from 3-8 mil and more preferably from 5-7 mil or any range or combination of ranges therein. The tie layers 18 preferably have a thickness from 0.2-1.2 mils and more preferably 0.6-0.8 mils. Thus, the overall thickness of the layered structure will be from 3.8 mils-14.9 mils.

Figure 2 shows an alternative embodiment having seven layers; This embodiment is the same as that in Figure 1 with the exception that the solution contact layer 16 is divided into three sublayers 16 a, b and c. Preferably the centrally disposed sublayer 16b of the solution contact 16 has a lower WVTR than its flanking sublayers 16a and 16c. Most preferably sublayers 16a and 16c are metallocene-catalyzed ULDPE and the central sublayer 16b is a metallocene-catalyzed low-density polyethylene. Preferably the flanking solution contact sublayers 16a and 16c have thicknesses of about 1 to 7 times, more preferably 2-6 times and most preferably 5 times thicker than the central sublayer 16b. Preferably the flanking solution contact sublayers 16a and 16c will have a thickness of from about 1-5 mils and most preferably 2.5 mils and the central solution contact layer 16b will have a thickness of about 0.2-1 mils and most preferably 0.5 mils.

Figure 3 shows another alternative embodiment that is the same in all respects to the multilayered structure of Figure 1 with the exception that the core layer 14 comprises a plurality of thin core sublayers. Preferably there are anywhere from 2-10 core sublayers. It may also be desirable to incorporate tie sublayers in between each of the core sublayers.

The tie sublayers; may be selected from those set forth above for bonding the inner and outer layers to the core layer.

The layered structures of the present invention are well suited for fabricating medical containers as they can be fabricated into containers and store medical solutions for extended periods of time without having large quantities of low molecular weight components migrating from the layered structure to the contained solution. For a 450 cm 2 surface area container containing 250 ml of saline for seven days, preferably, the quantity of low molecular weight additives, as measured by total organic carbon (TOG), will be less than l.Oppt, more preferably less than 100 ppm and most preferably less than 10 ppm.

The above layers may be processed into a layered structure by standard techniques well known to those of ordinary skill in the art and including cast coextrusion, coextrusion coating, or other acceptable process.

For ease of manufacture into useful articles, it is desirable that the layered structure can be welded using radio frequency welding techniques generally at about 27.12 MI- Therefore, the material should possess sufficient dielectric loss properties to convert the RF energy to thermal energy. Preferably, the outer layer 12 of the layered structure will have a dielectric loss of greater than 0.05 at frequencies within the range of 1-60 M4Hz within a temperature range of ambient to 250 'C.

Preferably, the layered structure is fabricated into films using a cast coextrusion process. The, process should be essentially free of slip agents and other low molecular weight -additives that may increase the extractables to an unacceptable level.

An illustrative, non-limiting example of the present multilayered structures is set out below. Numerous other examples can readily be envisioned in light of the guiding principles and teachings contained herein. The example-given herein is intended to illustrate the invention and not in any sense to limit the manner in which the invention can be practiced.

Example A five-layered structure was coextruded in accordance with the teachings of the present invention. The five-layered structure had an outer layer of nylon 12 (EMS America Grilon- Grilainid L20) having a thickness of 0.6 mil, a tie layer (BYNELO 4206 (DuPont)) having a thickness of 0.7 mit, a core layer of EVOH (EVAL® EVON LC-F 10 1 AZ) having a thickness of 1.0 mil, and a ULDPE (Dow AFFINITY@ PL1880) having a thickness of miL The structure was radiation sterilized using a cobalt source at a dosage of 40-45 kGys.

The table below shows how the oxygen permeability of the structure depends on temperature. The oxygen permeability was measured using a MoCon tester (Modem Controls, Minneapolis, MN). The test chamber had a relative humidity of 75% on the 02 side and a 90% relative humidity on the N 2 side to replicate a solution filled container in a high humidity environment.

TEMPERATURE °C 02 PERMEABILITY cc/l0 in/day 8 0.002 15 0.003 22 0.018 0.046 0.156 The water vapor transmission rate was also measured at 23 °C and at a humidity gradient of 90% yielding a WVTR of 0.035 g 120/100 in 2 /day.

It will be understood that the invention may be embodied in other specific forms without departing from the spirit or central characteristics thereof. The present example and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and the invention is not to be limited to the details given herein.

Claims (19)

1. A method of storing a medical solution containing a labile species comprising: providing a slip agent-free flexible container having an ethylene vinyl alcohol core layer disposed between a polyolefin solution contact layer and an outermost layer selected from the group consisting of polyamides and polyesters, the core layer having an oxygen permeability of less than 0.2 cc/100 in2/24 hrs; irradiating the container; and storing said solution containing a labile species in the flexible container.

2. The method of claim 1 wherein said polyolefin layer contains a polymer or copolymer of propylene, ethylene, butene-1, pentene-1, hexene-1, heptene- 1, octene-1, nonene-1 or decene-1.

3. The method of claim 1 wherein said polyolefin layer contains ultra low density polyethylene, low density polyethylene, linear low density polyethylene, medium density polyethylene, or high density polyethylene.

4. The method of claim 1 wherein the ethylene vinyl alcohol copolymer is coextruded with said polyolefin layer. The method of claim 1 wherein the oxygen permeability of said container is not more than 0.156 cc/100 in 2 /24 hrs at 40 0 C and an ambient relative humidity of 12/05/06

6. The method of claim 1 wherein the oxygen permeability of said container is not more than 0.046 cc/100 in2/24 hrs at 30°C and an ambient relative humidity of

7. The method of claim 1 wherein the oxygen permeability of said container is not more than 0.018 cc/100 in2/24 hrs at 22°C and an ambient relative humidity of

8. The method of claim 1 wherein the oxygen permeability of said container is not more than 0.003 cc/100 in 2 /24 hrs at 15°C and an ambient relative humidity of

9. The method of claim 1 wherein the oxygen permeability of said container is not more than 0.002 cc/100 in 2 /24 hrs at 8°C and an ambient relative humidity of A container for storing a medical solution containing a labile species comprising: an irradiated, slip agent-free flexible container having an ethylene vinyl alcohol copolymer core layer with an oxygen permeability of less than 0.2 cc/100 in 2 /24 hrs, the core layer disposed between a polyolefin solution contact layer and an outermost layer selected from the group consisting of polyamides and polyesters; and a solution containing a labile species in the container. 12/05/06

11. The container of claim 10 wherein said polyolefin layer contains a polymer or copolymer of propylene, ethylene, butene-1, pentene-1, hexene-1, heptene-1, octene-1, nonene-1 or decene-1.

12. The container of claim 10 wherein said polyolefin layer contains ultra low density polyethylene, low density polyethylene, linear low density polyethylene, medium density polyethylene, or high density polyethylene.

13. The container of claim 10 wherein the ethylene vinyl alcohol copolymer is coextruded with said polyolefin layer.

14. The container of claim 10 wherein the oxygen permeability of said container is not more than 0.156 cc/100 in 2 /24hrs at 40 0 C and an ambient relative humidity of The container of claim 10 wherein the oxygen permeability of said container is not more than 0.046 cc/100 in 2 /24 hrs at 30 0 C and an ambient relative humidity of

16. The container of claim 10 wherein the oxygen permeability of said container is not more than 0.018 cc/100 in/24 hrs at 22°C and an ambient relative humidity of

17. The container of claim 10 wherein the oxygen permeability of said container is not more than 0.003 cc/100 in 2 /24 hrs at 15°C and an ambient relative humidity of 12/05/06

18. The container of claim 10 wherein the oxygen permeability of said container is not more than 0.002 cc/100 in2/24 hrs at 80C and an ambient relative humidity of

19. The method of claim 1 wherein the irradiating further comprises exposing the container to 40 to 45 kGys of radiation to sterilize the container. The method of claim 1 further comprising leaching less than 1.0 ppt organic carbon from the container into the labile solution.

21. The container of claim 12 wherein the solution contains less than 1.0 ppt organic carbon leached from the container.

22. A method of storing a medical solution containing a labile species substantially as hereinbefore described with reference to the accompanying drawings.

23. A container for storing a medical solution containing a labile species substantially as hereinbefore described with reference to the accompanying drawings. Dated this 12 th day of May 2006 Baxter International Inc. Patent Attorneys for the Applicant PETER MAXWELL ASSOCIATES 12/05/06